Biomarkers

We focus on diseases with a high medical need for which novel therapeutics are (soon) available, but for which diagnostics are lacking. We employ phage display technology to develop antibodies to preselected high-potential biomarker candidates, including oxidatively modified and phosphorylated proteins. These antibodies are then further developed to be incorporated into a multiplex bead-based analysis to allow the measurement of multiple analytes from a small sample volume. Our aim is to use these biomarkers for early identification of disease onset, risk prediction, patient stratification and therapeutic monitoring.